Ep155: Valerie Daggett on Early Detection, and Treatment, of Alzheimer's
Mar 6, 2024
auto_awesome
Valerie Daggett, Founder and CEO of AltPep, discusses early detection of Alzheimer's through blood tests and therapeutic interventions. She shares her academic journey in protein studies, relocation for collaboration, and innovative approaches in detecting and treating Alzheimer's. The podcast highlights the importance of targeting toxic oligomers in pathology and the potential of blood-based diagnostics for amyloid diseases.
AltPEP focuses on early detection of toxic amyloid beta proteins in Alzheimer's using innovative peptide technology.
Valerie Daggett's transition from academia to entrepreneurship led to the development of peptides targeting toxic amyloid proteins.
AltPEP's peptide design aims to detect and clear toxic protein oligomers in Alzheimer's and Parkinson's before irreversible damage occurs.
AltPEP's engagement with the FDA and focus on clinical trials demonstrate a strategic approach towards diagnostic and therapeutic advancements.
Valerie Daggett's collaborative approach and AltPEP's inclusive strategy highlight a transformative impact on personalized disease management.
Deep dives
Development of a Novel Diagnostic and Therapeutic Strategy for Alzheimer's Disease
A company founded by Valerie Daggett, AltPEP, is developing a groundbreaking approach to diagnosing and treating Alzheimer's disease. They focus on early detection using a blood test that can identify toxic forms of amyloid beta protein. Valerie's academic background in bioengineering led to the creation of peptides that can distinguish toxic amyloid proteins. AltPEP secured funding and is moving towards clinical trials to validate their diagnostic and therapeutic solutions.
Evolution of Research and Transition to Business
Valerie Daggett's journey from academia to entrepreneurship involved translating her extensive research on protein folding into practical applications. Her collaboration with renowned scientists and clinicians helped develop alpha sheet structures to capture toxic amyloid proteins. The transition to leading AltPEP allowed her to apply these innovations in diagnosing and treating neurodegenerative diseases.
Innovative Alpha Sheet Peptides for Early Disease Intervention
AltPEP's peptide design targets toxic oligomers associated with Alzheimer's and Parkinson's diseases. These peptides not only detect toxic forms of proteins early on but also bind to and clear them out before causing irreversible damage. The company's approach aims at a complete solution for detecting and mitigating neurodegenerative diseases before symptoms manifest.
Strategic FDA Approval and Clinical Trial Progression
AltPEP's engagement with the FDA for their diagnostic assay showcases a remarkable leap towards clinical validation. By leveraging existing approvals and studying CSF and plasma samples, AltPEP is poised to accelerate diagnostic development. The company's focus on therapeutic IND enabling work and preclinical studies underpin their commitment to advancing towards human trials.
Collaborative Network and Future Plans for Disease Management
Valerie Daggett's collaborative approach involving diverse expertise, investors, and clinical partners underscores AltPEP's dedication to tackling neurodegenerative diseases comprehensively. Their inclusive strategy, combining diagnostics and therapeutics, sets the stage for a transformative impact on early disease management. The company's successful network integration and adaptive research approach position them well for future disease interventions.
Vision for Personalized Healthcare Solutions
AltPEP envisions a future where personalized diagnostic and therapeutic solutions revolutionize early disease intervention. By harnessing innovative peptide technology and leveraging regulatory approval pathways, the company is poised to make a significant impact on neurodegenerative disease management. With a strong foundation in research and an agile business model, AltPEP strives to pave the way for personalized healthcare solutions in Alzheimer's and Parkinson's disease.
Entrepreneurial Journey and Community Support
Valerie Daggett's entrepreneurial journey highlights the importance of a supportive network and collaborative spirit in driving innovation. Transitioning from academia to entrepreneurship, she found fulfillment in leading AltPEP's mission towards transforming disease management. The company's collective efforts, from funding to expertise, epitomize a united approach towards addressing significant unmet needs in healthcare.
Hope for Future Milestones and Impactful Healthcare Innovation
AltPEP's pursuit of FDA approvals, clinical trials, and therapeutic advancements signifies a promising trajectory in healthcare innovation. With a focus on transforming early disease detection and intervention, the company's commitment to novel peptide-based solutions offers hope for addressing complex neurodegenerative diseases. Valerie Daggett's visionary leadership and collaborative efforts underscore the potential for AltPEP to make a significant impact on personalized disease management.
Acknowledgment of Support and Optimism for Progress
Valerie Daggett appreciates the collective support from academic colleagues, investors, and advisors in advancing AltPEP's innovative approach to disease management. The company's progress in developing diagnostic solutions and therapeutic interventions signifies a transformative journey towards personalized healthcare solutions. With a strong foundation in research and strategic partnerships, AltPEP's optimism for future advancements underscores a shared commitment to improving patient outcomes.
